文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

普萘洛尔预防严重早产儿视网膜病变的有效性:一项系统综述与Meta分析

Effectiveness of Propranolol in Preventing Severe Retinopathy of Prematurity: A Comprehensive Systematic Review and Meta-Analysis.
PubMed 文献 · Am J Ophthalmol · 2023-11-17

该Meta分析纳入8项研究,评估口服普萘洛尔预防早产儿严重早产儿视网膜病变(ROP,定义为≥3期或需治疗)的效果。结果显示普萘洛尔组发生ROP的风险比为0.59(95%CI=0.42,0.82;P=.002;I²=41%),plus病变风险比为0.42(95%CI=0.23,0.78;P=.006;I²=0%),需激光光凝风险比为0.48(95%CI=0.31,0.74;P=.001;I²=2%),需玻璃体腔注射VEGF风险比为0.43(95%CI=0.24,0.74;P=.003;I²=0%)。结论认为口服普萘洛尔作为预防性治疗可成功预防严重ROP,但剂量和时机需结合研究人群谨慎考虑。

要点

  • 口服普萘洛尔预防严重ROP的总体风险比为0.59(95%CI=0.42,0.82;P=.002;I²=41%)。
  • 普萘洛尔组plus病变风险比为0.42(95%CI=0.23,0.78;P=.006;I²=0%)。
  • 需激光光凝风险比为0.48(95%CI=0.31,0.74;P=.001;I²=2%),需玻璃体腔注射VEGF风险比为0.43(95%CI=0.24,0.74;P=.003;I²=0%)。

核心结论

  • 口服普萘洛尔作为早产新生儿的预防性治疗可成功预防严重ROP。
  • 普萘洛尔的剂量和时机必须结合研究人群谨慎考虑,因为这些因素可能对观察到的结局和治疗成功有重大影响。

研究设计与样本

  • 研究设计为相关文献的Meta分析,遵循PRISMA指南系统评估截至2023年5月10日发表的文献。
  • 共识别3464篇论文(PubMed 2873篇、Scopus 39篇、Medline 67篇、Embase 16篇),筛选后最终纳入8项研究。
  • 纳入标准为使用β受体阻滞剂预防严重ROP(定义为≥3期或需治疗)的试验和观察性研究。

主要发现

  • 普萘洛尔使用与ROP疾病发生风险降低相关,总体风险比为0.59(95%CI=0.42,0.82;P=.002;I²=41%)。
  • plus病变的总体风险比为0.42(95%CI=0.23,0.78;P=.006;I²=0%)。
  • 需激光光凝的总体风险比为0.48(95%CI=0.31,0.74;P=.001;I²=2%)。
  • 需玻璃体腔注射VEGF的总体风险比为0.43(95%CI=0.24,0.74;P=.003;I²=0%)。
  • 本研究未发现统计学显著的异质性(P>.10,I²=50%),表明所选研究结果具有足够可比性和一致性。

关键数值与推荐

  • 严重ROP定义为≥3期或需治疗。
  • 普萘洛尔组ROP发生风险比为0.59(95%CI=0.42,0.82;P=.002;I²=41%)。
  • 普萘洛尔组plus病变风险比为0.42(95%CI=0.23,0.78;P=.006;I²=0%)。
  • 普萘洛尔组需激光光凝风险比为0.48(95%CI=0.31,0.74;P=.001;I²=2%)。
  • 普萘洛尔组需玻璃体腔注射VEGF风险比为0.43(95%CI=0.24,0.74;P=.003;I²=0%)。

临床怎么用

  • 口服普萘洛尔作为预防性治疗可成功预防早产新生儿严重ROP。
  • 作者认为普萘洛尔的剂量和时机必须结合研究人群谨慎考虑,因为这些因素可能对观察到的结局和治疗成功有重大影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To learn more about the effectiveness of oral propranolol as a therapeutic alternative for preterm newborns with pre-existing retinopathy of prematurity (ROP) as well as an early prevention method for ROP, one of the most common but avoidable causes of juvenile blindness. STUDY DESIGN: Meta-analysis of relevant literature. METHODS: A total of 3464 papers were identified, with 2873 from PubMed, 39 from Scopus, 67 from Medline, and 16 from Embase. After screening, finally, a total of 8 studies were deemed suitable for review. Following the PRISMA guidelines, published literature was systematically assessed up to May 10, 2023. Trials and observational studies were included in which beta blockage was used to prevent severe ROP (defined as stage ≥3 or requiring treatment). A total of 3646 papers were identified, with 2873 from PubMed, 39 from Scopus, 67 from Medline, and 16 from Embase. After screening, a total of 8 studies were deemed suitable for review. RESULTS: The use of propranolol is linked to a lower risk of disease development in ROP compared to other therapies or control groups, according to the overall risk ratio of 0.59 (95% CI = 0.42, 0.82; P = .002, I2 = 41%). Additionally, the overall risk ratio for plus disease is 0.42 (95% CI = 0.23, 0.78; P = .006, I2 = 0%), for laser photocoagulation is 0.48 (95% CI = 0.31, 0.74; P = .001; I2 = 2%), and for intravitreal injection of VEGF is 0.43 (95% CI = 0.24, 0.74; P = 0.003, I2 = 0%), suggesting that use of propranolol may reduce the likelihood of developing a disease such as plus disease, requiring laser photocoagulation or necessitating intravitreal injection of vascular endothelial growth factor for ROP, respectively. No statistically significant heterogeneity was found in this study (P > .10, I2 = 50%). It can be concluded from this that the results of the chosen studies were sufficiently comparable and consistent. CONCLUSION: This study showed that oral propranolol given as a preventive treatment in premature newborns successfully prevented severe ROP. Propranolol dosage and timing must now be carefully considered in the context of the study population, as these factors may have a major impact on the observed outcomes and treatment success.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Shafique MA, Haseeb A, Uddin MMN, et al. Effectiveness of Propranolol in Preventing Severe Retinopathy of Prematurity: A Comprehensive Systematic Review and Meta-Analysis. Am J Ophthalmol. 2023. PMID: 37979602. doi:10.1016/j.ajo.2023.11.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。